ADC Therapeutics
ADCT
41 hedge funds and large institutions have $35.4M invested in ADC Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 18 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7.31% less ownership
Funds ownership: 56.25% → 48.93% (-7.3%)
27% less funds holding
Funds holding: 56 → 41 (-15)
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
64% less capital invested
Capital invested by funds: $97.5M → $35.4M (-$62.1M)
78% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.63M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$665K |
| 3 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
+$386K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$178K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$5.93M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.63M |
| 3 |
SCM
Sio Capital Management
New York
|
-$966K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$775K |
| 5 |
Barclays
London,
United Kingdom
|
-$677K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$40K | -18,835 | Closed |
|
52
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$40.4K | -18,788 | Closed |
|
53
Jane Street
New York
| – | -$35.4K | -16,467 | Closed |
|
54
Verition Fund Management
Greenwich,
Connecticut
| – | -$31.5K | -14,649 | Closed |
|
|
CCG
55
Cypress Capital Group
Palm Beach,
Florida
| – | -$21.5K | -10,000 | Closed |
|
|
ACM
56
Aquatic Capital Management
Chicago,
Illinois
| – | -$5K | -2,300 | Closed |
|
57
Citigroup
New York
| – | -$3.94K | -1,834 | Closed |
|
58
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$215 | -100 | Closed |
|
|
SIC
59
Salem Investment Counselors
Winston Salem,
North Carolina
| – | -$76 | -35 | Closed |
|
ADCT Hedge Fund Activity: Q3 2023 in Review
41 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2023, worth a combined $35.4M — down 64% from $97.5M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ADCT and 4 opened new positions — a net loss of 14 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, adding an estimated $1.63M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $5.93M sold.
- 41 institutional investors held ADC Therapeutics (ADCT) as of Q3 2023, down from 56 in Q2 2023.
- Funds reported $35.4M of ADC Therapeutics stock for Q3 2023, down 64% quarter-over-quarter.
- 4 funds opened new ADC Therapeutics positions in Q3 2023 and 18 closed out, a net change of -14 holders.
- The largest ADC Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $1.63M added.
- The largest ADC Therapeutics seller in Q3 2023 was JP Morgan Chase, an estimated $5.93M sold.
Based on aggregated 13F filings for Q3 2023.